Senzar Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Senzar Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-61,304	Closed	-$412K	–	11
2018 Q2	$412K	Sell	61,304 -114,686	-65%	-$880K	1.19%	21
2018 Q1	$1.51M	Sell	175,990 -4,010	-2%	-$75.5K	0.48%	31
2017 Q4	$3.74M	Sell	180,000 -41,000	-19%	-$727K	0.96%	27
2017 Q3	$3.9M	Sell	221,000 -52,500	-19%	-$727K	0.95%	25
2017 Q2	$3.09M	Buy	+273,500	New	+$2.92M	0.76%	21

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Senzar Asset Management's PTGX Position: Q3 2018 in Review

Senzar Asset Management sold out of Protagonist Therapeutics (PTGX) in Q3 2018, closing a stake of 61,304 shares — an estimated $412K sold.

Senzar Asset Management first reported a position in PTGX in Q2 2017 and held it in 5 quarters. The position peaked at $3.9M in Q3 2017. 61 funds tracked by Wall St. Rank hold PTGX as of Q3 2018.

Senzar Asset Management reported no remaining Protagonist Therapeutics position as of Q3 2018 after selling out during the quarter.
Senzar Asset Management sold 61,304 Protagonist Therapeutics shares in Q3 2018, an estimated $412K.
Senzar Asset Management first reported a position in Protagonist Therapeutics in Q2 2017 and held it in 5 quarters.
Senzar Asset Management's Protagonist Therapeutics position peaked at $3.9M in Q3 2017.
61 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2018.

Based on Senzar Asset Management's 13F filing for Q3 2018.